I confess that I didn't look at Allenex prior to calling it spam.
I suspect it probably is spam. But it could just be a high risk speculation idea.
First timer coming to the Biotech Valuation thread saying the "unknown" company is growing fast just smells like spam to me.
The year over year comparisons from the company's annual report and the operating margins are not indicative of a "hot" prospect. to me, at least.
Following comes from a PDF of their annual report. Original is at:
allenex.com
Bottom of the page - financial reports.
ALLENEX
AB
(PUBL)
YEAR-
END REPORT
2012
For the fourth quarter October
-
December
?
Net sales for the quarter amounted to
SEK27.4 million (27.5).
Sales were impacted by a negative
currency effect of SEK1.2 million
compared to the same period last year
. Adjusted for currency effects, the growth rate was
4 percent.
?
Operating income (EBIT) for the quarter was SEK0.6million(-76.0)
,
with currency effects having a negative impact of SEK
1.4 million on results compared to the same period
last year
.
(
In 2011, earnings were impacted by impairment losses of SEK 74.6 million.
)
?
Operating margin for the quarter was 2 percent.
?
Earnings after tax for the quarter was SEK
0.9 million(-71.7).
?
Earnings per share for the quarter, basic and diluted, were
SEK0.03(-0.75).
For the January
-
December period
?
Net sales for the year amounted to SEK 112.7million(98.7)
,
corresponding to an increase of 14 percent
compared to last year.
(
Olerup GmbH became a part of the group on June 1, 2011).
Sales compared to 2011 were impacted by a negative currency effect of SEK 2.3 million.
?
Operating income(EBIT) for the year was SEK 7.9 million(-88.1)
, with currency effects having a negative impact of SEK 3.7 million on results
compared to last year
.
(
2011
results
were charged
with
impairment losses of
SEK
74
.6
million
.
)
?
Operating margin for the year was 7
percent
.
?
Earnings after tax for the year was SEK 0.3 million(-504.7)
.
(
2011
results were charged
with
i
m-
pairment losses of
SEK
489
.3 million
)
.
?
Earnings per share for the year, basic and diluted, were SEK0.04(-7.23)
.
Si
gnificant events after the year
end
?
The
Allenex
subsidiary
AbSorber
received
an
EU
grant
of EUR 215,000 over a three
-
year period
?
Allenex received a breakthrough order in the U.S. for SBT Resolver™
from a leading HLA typing l
a-
boratory. The yearly sales value is estimated at more than SEK 2 million |
